202 related articles for article (PubMed ID: 16433198)
1. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
Orlandi P; Barbara C; Bocci G; Fioravanti A; Di Paolo A; Del Tacca M; Danesi R
J Chemother; 2005 Dec; 17(6):663-7. PubMed ID: 16433198
[TBL] [Abstract][Full Text] [Related]
2. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
3. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
4. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids.
Nicholson KM; Bibby MC; Phillips RM
Eur J Cancer; 1997 Jul; 33(8):1291-8. PubMed ID: 9301458
[TBL] [Abstract][Full Text] [Related]
5. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
7. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
10. Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
Uematsu N; Zhao Y; Kiyomi A; Yuan BO; Onda K; Tanaka S; Sugiyama K; Sugiura M; Takagi N; Hayakawa A; Hirano T
Anticancer Res; 2018 Apr; 38(4):2101-2108. PubMed ID: 29599328
[TBL] [Abstract][Full Text] [Related]
11. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.
Gewirtz DA; Randolph JK; Chawla J; Orr MS; Fornari FA
Cancer Chemother Pharmacol; 1998; 41(5):361-9. PubMed ID: 9523731
[TBL] [Abstract][Full Text] [Related]
12. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
13. Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Weiss M; Giessler C; Kang W
Anticancer Drugs; 2006 Jan; 17(1):69-74. PubMed ID: 16317292
[TBL] [Abstract][Full Text] [Related]
14. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
17. Effects of α-Mangostin on Viability, Growth and Cohesion of Multicellular Spheroids Derived from Human Breast Cancer Cell Lines.
Scolamiero G; Pazzini C; Bonafè F; Guarnieri C; Muscari C
Int J Med Sci; 2018; 15(1):23-30. PubMed ID: 29333084
[No Abstract] [Full Text] [Related]
18. Idarubicin: a brief overview on pharmacology and clinical use.
Borchmann P; Hübel K; Schnell R; Engert A
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
20. Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing.
Gong X; Lin C; Cheng J; Su J; Zhao H; Liu T; Wen X; Zhao P
PLoS One; 2015; 10(6):e0130348. PubMed ID: 26090664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
